These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 9647301)

  • 1. Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis.
    Edwards S; Zvartau M; Clarke H; Irving W; Blumhardt LD
    J Neurol Neurosurg Psychiatry; 1998 Jun; 64(6):736-41. PubMed ID: 9647301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.
    Pozzilli C; Bastianello S; Koudriavtseva T; Gasperini C; Bozzao A; Millefiorini E; Galgani S; Buttinelli C; Perciaccante G; Piazza G; Bozzao L; Fieschi C
    J Neurol Neurosurg Psychiatry; 1996 Sep; 61(3):251-8. PubMed ID: 8795595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study on the relationship between infections and multiple sclerosis exacerbations.
    Buljevac D; Flach HZ; Hop WC; Hijdra D; Laman JD; Savelkoul HF; van Der Meché FG; van Doorn PA; Hintzen RQ
    Brain; 2002 May; 125(Pt 5):952-60. PubMed ID: 11960885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
    Arnold DL; Calabresi PA; Kieseier BC; Sheikh SI; Deykin A; Zhu Y; Liu S; You X; Sperling B; Hung S
    BMC Neurol; 2014 Dec; 14():240. PubMed ID: 25551571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
    Jacobs LD; Beck RW; Simon JH; Kinkel RP; Brownscheidle CM; Murray TJ; Simonian NA; Slasor PJ; Sandrock AW
    N Engl J Med; 2000 Sep; 343(13):898-904. PubMed ID: 11006365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
    Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
    BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum soluble intercellular adhesion molecule-I in MS: relation to clinical and Gd-MRI activity and to rIFN beta-Ib treatment.
    Trojano M; Avolio C; Ruggieri M; Defazio G; Giuliani F; Paolicelli D; Livrea P
    Mult Scler; 1998 Jun; 4(3):183-7. PubMed ID: 9762671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining interferon beta response status in multiple sclerosis patients.
    Rudick RA; Lee JC; Simon J; Ransohoff RM; Fisher E
    Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapies.
    McFarland HF; Stone LA; Calabresi PA; Maloni H; Bash CN; Frank JA
    Mult Scler; 1996 Nov; 2(4):198-205. PubMed ID: 9345374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 May; 18(1):68. PubMed ID: 29751787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-beta-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images.
    Gasperini C; Pozzilli C; Bastianello S; Giugni E; Horsfield MA; Koudriavtseva T; Galgani S; Paolillo A; Haggiag S; Millefiorini E; Fieschi C
    J Neurol Neurosurg Psychiatry; 1999 Nov; 67(5):579-84. PubMed ID: 10519861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatigue and magnetic resonance imaging activity in multiple sclerosis.
    Mainero C; Faroni J; Gasperini C; Filippi M; Giugni E; Ciccarelli O; Rovaris M; Bastianello S; Comi G; Pozzilli C
    J Neurol; 1999 Jun; 246(6):454-8. PubMed ID: 10431770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
    N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis.
    Prosperini L; Mancinelli CR; De Giglio L; De Angelis F; Barletta V; Pozzilli C
    Mult Scler; 2014 Apr; 20(5):566-76. PubMed ID: 23999607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial.
    Filippi M; Rovaris M; Inglese M; Barkhof F; De Stefano N; Smith S; Comi G
    Lancet; 2004 Oct 23-29; 364(9444):1489-96. PubMed ID: 15500893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of infection on exacerbations of multiple sclerosis.
    Panitch HS
    Ann Neurol; 1994; 36 Suppl(Suppl):S25-8. PubMed ID: 8017885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment.
    Avolio C; Filippi M; Tortorella C; Rocca MA; Ruggieri M; Agosta F; Tomassini V; Pozzilli C; Stecchi S; Giaquinto P; Livrea P; Trojano M
    Mult Scler; 2005 Aug; 11(4):441-6. PubMed ID: 16042227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.